<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9780">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690321</url>
  </required_header>
  <id_info>
    <org_study_id>Dropizol_patients</org_study_id>
    <secondary_id>2020-000396-20</secondary_id>
    <nct_id>NCT05690321</nct_id>
  </id_info>
  <brief_title>Opium Tincture Against Chronic Diarrhea - Patients</brief_title>
  <official_title>Opium Tincture Against Chronic Diarrhea - Patients An Investigator Initiated, Randomized Placebo-controlled, Double-blinded, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asbjørn Mohr Drewes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the mechanistic anti-propulsive effects of opium&#xD;
      tincture on the gastrointestinal tract of a cohort of patients with chronic diarrhea&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opium tincture is used a symptomatic drug against chronic diarrhea even though no clinical&#xD;
      studies have investigated the effect on gastrointestinal function. With this randomized,&#xD;
      double-blind, placebo-controlled cross-over trial in 16 patients with chronic diarrhea, we&#xD;
      wish to provide evidence-based insights into the effects of opium tincture on&#xD;
      gastrointestinal function. Additionally, effects on the central nervous system will be&#xD;
      investigated a tertiary aim.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel movement frequency</measure>
    <time_frame>From day 1 to 7</time_frame>
    <description>Difference in number of spontaneous bowel movements per day between arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal transit</measure>
    <time_frame>Measurement started on day 4 of each study period until expulsion of the capsule]</time_frame>
    <description>Difference in hours from ingestion of a wireless motility capsule to expulsion of the capsule during active and placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>From day 1 to 7 in each study period</time_frame>
    <description>Rated on the Bristol Stool Form Scale (ranging from type 1 - type 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil diameter</measure>
    <time_frame>Day 1, 4 and 7 in each study period</time_frame>
    <description>Measured in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General cognition</measure>
    <time_frame>Day 1, 4 and 7 in each study period</time_frame>
    <description>Evaluated using the Mini-Mental State Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction time</measure>
    <time_frame>Day 1, 4 and 7 in each study period</time_frame>
    <description>Measured in milliseconds (ms) from a sound was provided and until the participant pressed a button</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term memory</measure>
    <time_frame>Day 1, 4 and 7 in each study period</time_frame>
    <description>Measured as number of digits correctly remembered after visual presentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>Day 1, 4 and 7 in each study period</time_frame>
    <description>Measured on the Gastrointestinal Symptom Rating Score (GSRS) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation symptoms</measure>
    <time_frame>Day 1, 4 and 7 in each study period</time_frame>
    <description>Measured on the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Chronic Diarrhea</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of opium tincture (Dropizol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo (identical to opium tincture in taste and appearance)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opium tincture</intervention_name>
    <description>Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period</description>
    <arm_group_label>Active treatment</arm_group_label>
    <other_name>Dropizol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Signed informed consent before any study specific procedures&#xD;
&#xD;
               -  Able to read and understand Danish&#xD;
&#xD;
               -  Male or female with an age of 20 years or more&#xD;
&#xD;
               -  The researcher believes that the participant understands what the study entails,&#xD;
                  are capable of following instructions, can attend when needed, and are expected&#xD;
                  to complete the study.&#xD;
&#xD;
               -  The investigator will ensure that fertile female participants have a negative&#xD;
                  pregnancy test before each treatment visit and use contraception during the&#xD;
                  entity of the study.&#xD;
&#xD;
               -  Specific underlying pathophysiology has been identified, but targeted treatment&#xD;
                  (e.g. antibiotics or bile acid sequestrants) and treatment with loperamide has&#xD;
                  failed.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  No specific underlying pathophysiology has been identified and treatment with&#xD;
             loperamide has failed.&#xD;
&#xD;
          -  At least 6 months post-surgery in the gastrointestinal tract&#xD;
&#xD;
          -  No sign of cancer at standard clinical follow-up&#xD;
&#xD;
          -  Chronic diarrhea defined as at least 3 daily bowel movements for the last week&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Known allergy towards pharmaceutical compounds similar to Dropizol.&#xD;
&#xD;
               -  Participation in other studies within 14 days of first visit (1 year if opioids&#xD;
                  involved).&#xD;
&#xD;
               -  Expected need of medical/surgical treatment during the study&#xD;
&#xD;
               -  History of psychiatric illness (e.g. mental retardation, schizophrenia, major&#xD;
                  depression)&#xD;
&#xD;
               -  History of substance abuse (e.g. alcohol, THC, benzodiazepine, central stimulants&#xD;
                  and/or opioids)&#xD;
&#xD;
               -  Family history of substance abuse&#xD;
&#xD;
               -  Known major stenosis of the intestines&#xD;
&#xD;
               -  Known severe decreased renal function (defined as eGFR below 30)&#xD;
&#xD;
               -  Known severe decreased hepatic function (defined as Child-Pugh class B or higher)&#xD;
&#xD;
               -  Treatment with MAO- inhibitors during the entity of the study&#xD;
&#xD;
               -  Severe COPD or acute severe asthma (defined as FEV1 below 50 % or acute ongoing&#xD;
                  exacerbation)&#xD;
&#xD;
               -  Known cor pulmonale&#xD;
&#xD;
               -  Female participants that are lactating&#xD;
&#xD;
               -  Medicine known to affect gastrointestinal motility must not be initiated during&#xD;
                  the entity of the study&#xD;
&#xD;
               -  Treatment with opium tincture during the last month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asbjørn Mohr Drewes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Okdahl</last_name>
    <phone>97663520</phone>
    <email>t.okdahl@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asbjørn Mohr Drewes</last_name>
    <email>amd@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Okdahl</last_name>
      <phone>97663520</phone>
      <email>t.okdahl@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Asbjørn Mohr Drewes</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Krogh</last_name>
      <phone>23385937</phone>
      <phone_ext>+45</phone_ext>
      <email>Klaukrog@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 10, 2023</last_update_submitted>
  <last_update_submitted_qc>January 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Asbjørn Mohr Drewes</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diarrhea</keyword>
  <keyword>Gastrointestinal transit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data can by provided upon request</ipd_description>
    <ipd_access_criteria>Researchers who provide a methodological sound proposal</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

